Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
- 2021年03月12日 14:00:00
- テクノロジー
- JCN Newswire
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
Yvonne Lungershausen, CEO, Avance Clinical said:
"As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results. Atossa Therapeutics have tapped the full scope of our CRO services including ClinicReady, our scientific and medical affairs specialist team. Australian clinical trials are recognized globally for their speed and accuracy and the fact that the clinical data is accepted by all major regulatory authorities including the FDA. Increasingly our clients are also tapping the generous 43.5% Australian Government rebate to support their clinical research."
According to Atossa Therapeutics:
Atossa Therapeutics today announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa's proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home.
Final analysis of the data from the study indicates that there were no serious adverse events, no discontinuations, no bronchospasms, and only one subject of the 32 subjects in the study experienced adverse events that were considered moderate in severity and all other adverse events were considered mild.
Atossa's assessment is that AT-301 nasal spray was safe and well tolerated in this study. The most common treatment-related adverse events observed with AT-301 treatment with either single or multiple doses were nasal discomfort and sneezing.
"The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301,"commented Steven Quay, M.D., Ph.D., Atossa's President and CEO.
Atossa believes that AT-301 nasal spray will play an important role alongside the traditional vaccines now being deployed, particularly as it becomes clear that it will take months or years for vaccines to be administered around the world.
The Phase 1 study was a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects who were divided into two study groups.
Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Part B was a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses.
The primary objectives of the study were to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives were to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation.
The study was being conducted in Australia.
See full announcement here. https://tinyurl.com/6fchfvh2
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5-6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
Chris Thompson
media@avancecro.com
Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com
【巨人】長島三奈さん背番号「3」でファーストピッチ「父が喜んでるのがすごくうれしい」
ゴジラ-1.0がAmazonプライム・ビデオで配信開始、追加料金無しで観られるのはありがたい!と話題に
“総利益100億円”著名投資家「何も言わず何も聞かず750万振り込んで」無茶要求明かす
アンミカ「名前の由来」明かす「当時は子が付かないだけでもかなり華やかな雰囲気がしたもの」
【阪神】岡田彰布監督のレアシーン 3点差6回2死満塁で梅野隆太郎へ自ら一言、ベンチでにやり
【阪神】大山悠輔が8回にこの日2本目のアーチ 2年ぶり1試合複数本塁打で自身10度目
上沼恵美子、新幹線男性客の「あぁ?」態度に怒り「あんたが間違えてんねん」
アンジャ児島一哉、ダチョウ肥後娘からの手紙「お父さんは“おでん”ばかりで嫌」明かし騒然
石原良純「よく死人が出なかった」叔父裕次郎さんが出演した「黒部の太陽」の舞台裏語る
長嶋一茂「そこに水を入れてコイを飼えるんじゃないかと」”まさかの場所”で魚飼った幼少期
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
今田美緒(23)ブレイク前の恥ずかしい映像が流出、けしからんと話題に
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
元なでしこタレント、引退の仰天理由明かしスタジオ悲鳴 きっかけはXの投稿だった
水原一平容疑者が胴元側に支払ったお金、カジノを通じ現金化されていた
蟹江敬三さん長男が子役・若山耀人容疑者の逮捕に嘆息「ここまでの転落人生は稀に見る悪例」
透け透けハイレグあまつまりな「目のやり場に困る…だがしっかり目に焼き付けさせてもらうっ 」
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
深夜のファミリーマート徘徊、必ず入っている「フエラムネのミニチュアおもちゃ付」を探し求めた結果……
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
群馬県草津町冤罪事件、フリーライターの男に懲役1年の求刑がここまで話題にならない理由
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
ゴジラ-1.0がAmazonプライム・ビデオで配信開始、追加料金無しで観られるのはありがたい!と話題に
【巨人】長島三奈さん背番号「3」でファーストピッチ「父が喜んでるのがすごくうれしい」
“総利益100億円”著名投資家「何も言わず何も聞かず750万振り込んで」無茶要求明かす
アンミカ「名前の由来」明かす「当時は子が付かないだけでもかなり華やかな雰囲気がしたもの」
【阪神】岡田彰布監督のレアシーン 3点差6回2死満塁で梅野隆太郎へ自ら一言、ベンチでにやり
【阪神】大山悠輔が8回にこの日2本目のアーチ 2年ぶり1試合複数本塁打で自身10度目
上沼恵美子、新幹線男性客の「あぁ?」態度に怒り「あんたが間違えてんねん」
アンジャ児島一哉、ダチョウ肥後娘からの手紙「お父さんは“おでん”ばかりで嫌」明かし騒然
石原良純「よく死人が出なかった」叔父裕次郎さんが出演した「黒部の太陽」の舞台裏語る
長嶋一茂「そこに水を入れてコイを飼えるんじゃないかと」”まさかの場所”で魚飼った幼少期